Feed AVTX
AV

Avalo Therapeutics, Inc.

AVTX · NASDAQ

$16.17 -0.58% (-$0.09)
1M -16.09%
Market Cap $850.0M
P/E Ratio -
Div. Yield -
ROE 58.03%

Bulios Fair Price

$9.16

43.4% downside

Trenutna cena

$16.17

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica AVTX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
45 /100
Fair
P/B 1.89x
P/S 14,406.50x
P/FFO N/A
Growth
0 /100
Declining
Rev. growth 85.16%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak
Net margin 170,056.00%
Op. margin 154,844.00%
FCF margin 112,505.00%
Quality
0 /100
Poor
ROE 58.03%
ROA 20.44%
Asset turnover 0.00x
Debt
100 /100
Low
Current ratio 19.31x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
56 /100
Moderate
Rev. volatility 6.44%
EPS volatility 99.59%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AVTX
Online

O podjetju

Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Garry A. Neil

Employees

33

Headquarters

Wayne

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.